Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotoxin therapy of hematological malignancies.

Literature DB >> 8647523

Immunotoxin therapy of hematological malignancies.

L Pasqualucci¹, L Flenghi, A Terenzi, A Bolognesi, F Stirpe, B Bigerna, B Falini.

Abstract

Entities: Disease

Mesh：

Substances：
Immunotoxins

Year: 1995 PMID： 8647523

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Authors: Holly J Meany; Nita L Seibel; Mark Krailo; Doojduen Villaluna; Zhengjia Chen; Paul Gaynon; Joseph P Neglia; Julie R Park; Raymond Hutchinson; Judith K Sato; Robert J Wells; William G Woods; Gregory Reaman
Journal: J Immunother Date: 2015-09 Impact factor: 4.456

Review 2. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors: Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal: Toxins (Basel) Date: 2011-06-22 Impact factor: 4.546

Review 3. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors: Franco Dosio; Paola Brusa; Luigi Cattel
Journal: Toxins (Basel) Date: 2011-07-14 Impact factor: 4.546

4. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.

Authors: A Klimka; S Barth; B Matthey; R C Roovers; H Lemke; H Hansen; J W Arends; V Diehl; H R Hoogenboom; A Engert
Journal: Br J Cancer Date: 1999-06 Impact factor: 7.640

Immunotoxin therapy of hematological malignancies.

1. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Review 2. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Review 3. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

4. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.

Review 5. Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.

Review 6. Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.

Review 7. Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.

8. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.

Review 9. Saporin-S6: a useful tool in cancer therapy.

Review 10. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.